ASCO 2022 Conference Coverage
Lecture Summary - ASCO 2022 on the Addition of Carfilzomib as a Third Agent in Lenalidomide-Refractory MM: Switching From Doublet to Triplet
By
ASCO 2022 Conference Coverage
FEATURING
Claudio Cerchione
By
ASCO 2022 Conference Coverage
FEATURING
Claudio Cerchione
Login to view comments.
Click here to Login
Myeloma